Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy with a poor prognosis. We conducted a retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of tucidinostat in patients with relapsed/refractory ATL who had not undergone transplantation. Between October 2021 and July 2023, 24 patients aged 41 to 88 years (median, 73.4 years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated as key outcomes. ORR and DCR reached 54.2% and 91.7%, respectively. The median PFS was 3.95 months, and OS was 8.04 months, which were not inferior to the results of a phase IIb study. The influential factors for PFS were age ≥ 75 years and high soluble IL-2 receptor (sIL-2R) levels above 5000 U/mL at the start of treatment. Favorable patients without these factors achieved a PFS of 11.4 months. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.
Authors
- Keiichi Akizuki (ORCID: https://orcid.org/0000-0003-0031-3456)
- Ayako Kamiunten (ORCID: https://orcid.org/0000-0002-6347-4305)
- Taisuke Uchida (ORCID: https://orcid.org/0000-0003-4511-4901)
- Kengo Matsumoto (ORCID: https://orcid.org/0000-0002-1074-026X)
- Takuro Kameda (ORCID: https://orcid.org/0000-0003-0100-1710)
- Yoko Kubuki (ORCID: https://orcid.org/0000-0002-0763-9136)
- Aki Kuroki
- Tomonori Hidaka (ORCID: https://orcid.org/0000-0002-7018-3653)
- Kotaro Shide (ORCID: https://orcid.org/0000-0002-0046-3254)
- Kentaro Nagamine (ORCID: https://orcid.org/0000-0001-7457-8487)
- Haruko Shimoda
- Kiyoshi Yamashita
- Masayoshi Karasawa
- Junzo Ishizaki
- Yuki Tahira (ORCID: https://orcid.org/0000-0001-6640-4559)
- Masaaki Sekine (ORCID: https://orcid.org/0000-0001-5481-3451)
- Seiichi Sato (ORCID: https://orcid.org/0000-0003-4778-3391)
- Kazuya Shimoda (ORCID: https://orcid.org/0000-0002-2555-8188)
- Kouichi Maeda
- Hiroshi Kawano (ORCID: https://orcid.org/0000-0001-9812-4615)
- Hideki Yamaguchi (ORCID: https://orcid.org/0000-0003-2319-7988)
- Masanori Takeuchi
- Takanori Toyama
- Ryoma Ikeda
- Noriaki Kawano
Institutions
- University of Miyazaki (JP)
- Miyazaki Prefectural Hospital (JP)
- Koga Hospital (JP)
- National Institute of Technology, Miyakonojo College (JP)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s12185-025-03963-9
- Citations
- 2
- Primary Topic
- T-cell and Retrovirus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- University of Miyazaki Hospital
- University of Miyazaki